Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab in Early Relapsing Multiple Sclerosis
NCT07225361Phase 4Recruiting
- Sponsor
- Northwestern University
- Start
- Nov 2025
- Primary completion
- Mar 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ublituximab in multiple sclerosis (MS), sponsored by Northwestern University. Started Nov 2025; status: recruiting.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07225361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225361.